Cynata Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Cynata Therapeutics kazanç ve gelirinin sırasıyla yıllık 34.1% ve 70.4% oranında artması tahmin edilirken, EPS'nin yıllık 54.2% oranında büyümesi bekleniyor.

Anahtar bilgiler

34.1%

Kazanç büyüme oranı

54.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	70.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	05 Aug 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:51S - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2026	7	-5	-4	-4	1
6/30/2025	1	-8	-8	-8	1
6/30/2024	2	-10	-10	-10	N/A
3/31/2024	2	-12	-11	-11	N/A
12/31/2023	2	-14	-12	-12	N/A
9/30/2023	2	-14	-13	-13	N/A
6/30/2023	2	-14	-14	-14	N/A
3/31/2023	2	-12	-12	-12	N/A
12/31/2022	3	-9	-10	-10	N/A
9/30/2022	5	-7	-7	-7	N/A
6/30/2022	8	-5	-3	-3	N/A
3/31/2022	8	-5	-2	-2	N/A
12/31/2021	8	-4	-1	-1	N/A
9/30/2021	5	-6	-3	-3	N/A
6/30/2021	2	-8	-5	-5	N/A
3/31/2021	2	-7	-5	-5	N/A
12/31/2020	3	-6	-5	-5	N/A
9/30/2020	5	-5	-4	-4	N/A
6/30/2020	7	-4	-3	-3	N/A
3/31/2020	6	-6	-5	-5	N/A
12/31/2019	4	-8	-7	-7	N/A
9/30/2019	3	-8	-7	-7	N/A
6/30/2019	1	-8	-7	-7	N/A
3/31/2019	1	-7	-6	-6	N/A
12/31/2018	1	-6	-5	-5	N/A
9/30/2018	1	-5	-4	-4	N/A
6/30/2018	1	-5	-4	-4	N/A
3/31/2018	1	-5	N/A	-4	N/A
12/31/2017	1	-5	N/A	-5	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-5	N/A	-4	N/A
3/31/2017	2	-4	N/A	-3	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-5	N/A	-4	N/A
3/31/2016	1	-5	N/A	-4	N/A
12/31/2015	1	-5	N/A	-4	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	0	-4	N/A	-3	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-2	N/A
3/31/2014	0	-3	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 51S önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 51S önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 51S önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 51S şirketinin gelirinin (yıllık 70.4% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 51S şirketinin gelirinin (yıllık 70.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 51S 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Cynata Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024

New major risk - Financial position

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001

New major risk - Revenue and earnings growth

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

New major risk - Financial position

Cynata Therapeutics Limited Announces Management Appointments

Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial

Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents

Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial

Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022

Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council

Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022

Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal

Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma

Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs

Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial

United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD

Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Commences DFU Clinical Trial

Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial

Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial

Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs

New 90-day low: €0.36

New 90-day low: €0.39

Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences

Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells

New 90-day high - €0.57

New 90-day high - €0.49

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin